CO5611165A2 - Composicion farmaceutica dispersable para el trataiento de mastitis y trastornos oticos - Google Patents

Composicion farmaceutica dispersable para el trataiento de mastitis y trastornos oticos

Info

Publication number
CO5611165A2
CO5611165A2 CO05094077A CO05094077A CO5611165A2 CO 5611165 A2 CO5611165 A2 CO 5611165A2 CO 05094077 A CO05094077 A CO 05094077A CO 05094077 A CO05094077 A CO 05094077A CO 5611165 A2 CO5611165 A2 CO 5611165A2
Authority
CO
Colombia
Prior art keywords
phenylephene
antibacterial agent
agent
administered
pharmaceutical composition
Prior art date
Application number
CO05094077A
Other languages
English (en)
Inventor
Nancy Britten
John W Burns
John W Hallberg
Niki A Waldron
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5611165A2 publication Critical patent/CO5611165A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Un método de tratamiento y/o prevención de un estado infeccioso en un órgano que contene fluido que tiene un orificio exterior natural, método que comprende administrar un agente antibacteriano al órgano a través del orificio exterior y administrar con dicho agente antibacteriano en terapia de combinación un segundo agente seleccionado del grupo que consiste en agentes anti-inflamatorios, analgésicos y antipiréticos, en el que dicho agente antibacteriano se administra como una composición farmacéutica que comprende dicho agente antibacteriano y un vehículo que comprende (a) un aceite anfipático que es dispersable en agua e insoluble en etanol, (b) cera microcristalina y (c) un excipiente no acuoso aceptable iarmacéuticamente.2.- El método de la reivindicación 1, en el que el estado infeccioso es una enfermedad de una ubre de un animal productor de leche, y en el que la composición que comprende el agente antibacteriano se administra por infusión intramamaria.3.- El método de la reivindicación 1, en el que el estado infeccioso es un trastorno de un oído de un sujeto o una complicación asociada con tal trastorno, y en el que la composición que comprende el agente antibacteriano se administra por infusión ótica.4.- El método de la reivindicación 1, en el que el segundo agente se administra como una composición farmacéutica que comprende dicho segundo agente y un vehículo que comprende (a) un aceite anfipático que es dispersable en agua e insoluble en etanol, (b) cera microcristalina y (c) un excipiente no acuoso aceptable farmacéuticamente.5.- El método de la reivindicación 1, en el que el agente antibacteriano se selecciona del grupo constituido por antibióticos de tipo penicilina naturales y sintéticos, cefalosporinas, macrolidos, lincosamidas, pleuromutilinas, polipéptidos, polimixinas, sulfonamidas, cloranfenicol, tianfenicol, florfenicol, antibióticos de tipo tetraciclina, quinolonas, fluoroquinolonas, tiamulina, ciprofloxacina, colistina, domeclociclina, mafénido, metaciclina, norfloxacina, ofloxacina, pirimetamina, sulfadiazina plata, sulfacetamida, sulfisoxazol, tobramicina, vanemulina, oxazolidinonas, glicopéptidos, aminoglicósidos y aminociclitoles, anfenicol, ansamicina, carbafenem, cefalmicina, vancomicina, monobactam, oxacefem, antibacterianos sistémicos, ...
CO05094077A 2003-03-20 2005-09-16 Composicion farmaceutica dispersable para el trataiento de mastitis y trastornos oticos CO5611165A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45620103P 2003-03-20 2003-03-20

Publications (1)

Publication Number Publication Date
CO5611165A2 true CO5611165A2 (es) 2006-02-28

Family

ID=33030090

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05094077A CO5611165A2 (es) 2003-03-20 2005-09-16 Composicion farmaceutica dispersable para el trataiento de mastitis y trastornos oticos

Country Status (19)

Country Link
US (1) US20040214753A1 (es)
EP (1) EP1608406A1 (es)
JP (1) JP2006520778A (es)
KR (1) KR100765614B1 (es)
CN (1) CN1761486A (es)
AR (1) AR043651A1 (es)
AU (1) AU2004222518A1 (es)
BR (1) BRPI0408559A (es)
CA (1) CA2519589A1 (es)
CL (1) CL2004000471A1 (es)
CO (1) CO5611165A2 (es)
MX (1) MXPA05010019A (es)
NO (1) NO20054777L (es)
NZ (1) NZ541780A (es)
RU (1) RU2321423C2 (es)
TW (1) TWI265809B (es)
UY (1) UY28236A1 (es)
WO (1) WO2004082719A1 (es)
ZA (1) ZA200506531B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
AU2003299574A1 (en) * 2002-12-02 2004-06-23 Byocoat Llc Composition ad method for treating plant fungal disease
JP4691018B2 (ja) * 2003-03-05 2011-06-01 ビオコート エンタープライジズ， インコーポレイテッド 抗菌溶液およびプロセス
EP1568369A1 (en) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
EP1740214B1 (en) * 2004-04-22 2007-10-03 Pfizer Products Incorporated Method of stabilizing disordered cefovecin sodium salt
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
AT501376B1 (de) * 2005-01-17 2010-11-15 Pregenzer Bruno Glucokortikoid-hältiges arzneimittel
WO2007039417A1 (en) * 2005-09-30 2007-04-12 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing meloxicam
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US20090317364A1 (en) * 2006-07-10 2009-12-24 Chandrakant Laxminarayan Rathi Novel compositions for prevention and treatment of mastitis and metritis
CA2860295C (en) * 2007-02-08 2018-01-30 Medtronic Xomed, Inc. Solvating system and sealant for medical use
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
BRPI0700969A (pt) * 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
US20100298386A1 (en) * 2007-10-03 2010-11-25 Burwell Steven R Compositions and methods for treating mastitis
JP2011524367A (ja) 2008-06-12 2011-09-01 メドトロニック・ゾーメド・インコーポレーテッド 慢性の創傷を治療するための方法
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20100086576A1 (en) * 2008-10-06 2010-04-08 Myntti Matthew F Antimicrobial composition and methods of making and using same
CN101953784B (zh) * 2009-07-16 2012-02-08 中国农业大学 含阿莫西林、硫酸粘菌素和泼尼松龙的兽用混悬液及其制备方法
CA2777366C (en) * 2009-10-12 2023-11-14 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
MX2012010077A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Vetmed Uso de meloxicam para el tratamiento a largo plazo de trastornos musculoesqueleticos en gatos.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US10653133B2 (en) 2011-05-10 2020-05-19 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
BRPI1103782A2 (pt) * 2011-08-19 2013-07-30 Eurofarma Lab Ltda produto veterinÁrio para tratamento de mastite, pre composiÇço antibiàtica a anti inflamatària, kit, mÉtodo de preparaÇço uso e mÉtodo de tratamento de mastite
CN102784161A (zh) * 2012-08-01 2012-11-21 张吉川 一种治疗急慢性中耳炎的特效滴耳液
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104825474B (zh) * 2015-04-30 2018-02-06 中国农业科学院兰州畜牧与兽药研究所 一种治疗动物体表损伤的药物组方及其制备工艺
AU2016256858B2 (en) * 2015-05-06 2020-10-08 Zoetis Services Llc Hydrogel formulation with mild adhesion
US10434097B1 (en) 2015-09-14 2019-10-08 Gateway Biotechnology, Inc. Methods and compositions for treating hearing disorders
MX2019002835A (es) 2016-09-13 2019-09-04 Allergan Inc Composiciones no proteínicas de toxina clostridial.
CN107252441A (zh) * 2017-08-07 2017-10-17 咸阳职业技术学院 一种治疗奶牛乳腺炎的药物组合物及其制备方法
US11918653B2 (en) * 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
JP7323630B2 (ja) * 2019-03-06 2023-08-08 ゾエティス・サービシーズ・エルエルシー 使用準備が整った注射用製剤
CN114727997A (zh) * 2019-08-27 2022-07-08 卡希夫生物科学有限公司 用于治疗疼痛的化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636194A (en) * 1969-10-23 1972-01-18 Douglas G Parizeau Composition and method for treating mastitis with therapeutic agents
DE2063896A1 (de) * 1970-12-28 1972-07-20 Dynamit Nobel Ag, 5210 Troisdorf Salbengrundlagen auf der Basis von Triglyceriden gesättigter mittelkettiger Fettsäuren und Verfahren zu deren Herstellung
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
RO118200B1 (ro) * 1995-05-25 2003-03-28 Gd Searle & Co Chicago Procedeu pentru obtinerea (3-haloalchil-1h-pirazol-1-il)-arilsulfonamidelor
AU708540B2 (en) * 1995-06-06 1999-08-05 Bayer Intellectual Property Gmbh Non-irritation, nonsensitizing, non-ototoxic otic anti-bacterial compositions
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
GEP20032998B (en) * 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
AP2002002582A0 (en) * 1999-12-23 2002-09-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6548527B2 (en) * 2000-03-27 2003-04-15 The General Hospital Corporation Treatments for immune-mediated ear disorders
EP1282435A2 (en) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
WO2001094369A2 (en) * 2000-06-08 2001-12-13 The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
CA2410632A1 (en) * 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
JP2006520778A (ja) 2006-09-14
EP1608406A1 (en) 2005-12-28
US20040214753A1 (en) 2004-10-28
TWI265809B (en) 2006-11-11
AR043651A1 (es) 2005-08-03
RU2321423C2 (ru) 2008-04-10
KR100765614B1 (ko) 2007-10-09
MXPA05010019A (es) 2005-11-17
CN1761486A (zh) 2006-04-19
AU2004222518A1 (en) 2004-09-30
CA2519589A1 (en) 2004-09-30
UY28236A1 (es) 2004-11-08
TW200507852A (en) 2005-03-01
KR20050114245A (ko) 2005-12-05
ZA200506531B (en) 2006-11-29
NO20054777L (no) 2005-10-17
BRPI0408559A (pt) 2006-03-21
NZ541780A (en) 2008-06-30
CL2004000471A1 (es) 2005-04-22
WO2004082719A1 (en) 2004-09-30
RU2005126363A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
CO5611165A2 (es) Composicion farmaceutica dispersable para el trataiento de mastitis y trastornos oticos
CO5650245A2 (es) Formulaciones dispersable de un agente anti-inflamatorio
ES2668909T3 (es) Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
AU2002361918B2 (en) Aerosolized decongestants for the treatment of sinusitis
BR0317104A (pt) Composições farmacêuticas dispersáveis
UY28235A1 (es) Formulación dispersable de un agente antiinflamatorio
CA2477044A1 (en) Ophthalmic formulation with gum system
ES2694775T3 (es) Composiciones que comprenden finafloxacina y métodos de tratamiento de infecciones oftálmicas, óticas y nasales
PE20030575A1 (es) Soluciones de meloxicam estables y muy concentradas para la inyeccion sin aguja
JP2018522070A (ja) 白内障の処置用組成物
JP2015524444A5 (es)
JP2011520894A5 (es)
JP2019147802A (ja) ジブチルヒドロキシトルエンの安定化方法
KR20210054068A (ko) 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
JP2006039529A (ja) コンタクトレンズ用組成物
JP6724106B2 (ja) クロルフェニラミン又はその塩の安定化方法
US20160022595A1 (en) Bioadhesive and biodegradable and formulations that provide sustained release of antimicrobials, bacteriophages and anti-inflammatory medications for inactivation of biofilms and the treatment of rhinosinusitis and other infections
BRPI0413478A (pt) solução farmacêutica aquosa compreendendo oximetazolina e/ou xilometazolina
WO2016063265A2 (pt) Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos
JP6618262B2 (ja) ジブチルヒドロキシトルエンの安定化方法
BR0112035A (pt) peptìdeos antimicrobianos de novispirin
WO2020044114A3 (en) Methotrexate pharmaceutical composition
Maljkovic et al. CASE REPORT: Laser-Assisted Treatment of Sialolithiasis
CN203829288U (zh) 新型泪道探通冲洗针

Legal Events

Date Code Title Description
FC Application refused